粉防己:治疗糖尿病肾病的潜力候选药物
糖尿病肾病是糖尿病常见微血管并发症,目前缺乏有效逆转手段。粉防己作为中药,其活性成分粉防己碱/青藤碱和防己诺林碱可通过调节炎症、氧化应激、肾小球内皮功能、足细胞损伤及脂代谢等多途径发挥肾脏保护作用。
要点
- 粉防己活性成分经多途径发挥肾脏保护作用
- 调节炎症与氧化应激是核心机制之一
- 改善肾小球内皮功能与足细胞损伤亦相关
核心结论
- 粉防己主要活性成分粉防己碱/青藤碱和防己诺林碱通过多途径发挥肾脏保护作用,为DKD新药开发提供理论依据。
研究设计与样本
- 聚焦粉防己主要活性成分经多途径发挥肾脏保护作用的分子机制研究。
主要发现
- 粉防己活性成分通过调节炎症反应、拮抗氧化应激、改善肾小球内皮功能、调节足细胞损伤及干预脂代谢紊乱发挥肾脏保护作用。
临床怎么用
- 为糖尿病肾病的潜在治疗提供中药活性成分机制依据,提示粉防己活性成分可能作为候选药物进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic kidney disease (DKD) is a common microvascular complication of diabetes. With the continuous rise in the prevalence of diabetes, it has become the primary cause of end-stage renal disease. Currently, there are no effective clinical treatments available to reverse the progression of DKD. Stephania tetrandra S. Moore, a traditional Chinese medicine, has demonstrated significant value in the prevention and treatment of DKD due to its active components. This study focuses on exploring the molecular mechanisms through which the primary active components of S. tetrandra, tetrandrine/sinomenine and fangchinoline, exert renal protective effects via multiple pathways, including regulating inflammatory responses, antagonizing oxidative stress, improving glomerular endothelial function, modulating podocyte damage, and intervening in lipid metabolism disorders. These findings provide a theoretical basis for the development of novel therapeutic agents for DKD.
引用
- Wang W, Li J, Yan Y, et al. Stephania tetrandra S. Moore: a promising candidate drug for treating diabetic kidney disease. Front Pharmacol. 2025. PMID: 41031161. doi:10.3389/fphar.2025.1651023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。